BioMarin settles patent disputes with Ascendis; gets 20% US royalty on Yuviwel sales

BIOMARIN PHARMACEUTICAL INC

Ascendis pays 20% of US net sales and 18% of EU/Brazil/South Korea net sales, retroactive to first commercial sale, until May 2030.
BioMarin grants non-exclusive worldwide license to its CNP patents for Yuviwel (navepegritide) across all indications, incl. achondroplasia.
All pending litigation dismissed with prejudice, including ITC Section 337 investigation and cases in Brazil, Denmark, Germany, South Korea, and N.D. Cal.
Binding term sheet signed Aug 30, 2026; parties to finalize definitive agreement by Sept 24, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.